Tocilizumab promotes repair of spinal cord injury by facilitating the restoration of tight junctions between vascular endothelial cells.

Yang LuoFei YaoYi ShiZhenyu ZhuZhaoming XiaoXingyu YouYanchang LiuShuisheng YuDasheng TianLi ChengMeige ZhengJuehua Jing

Published in: Fluids and barriers of the CNS (2023)

The application of Tocilizumab to antagonize IL-6R can effectively reduce the expression of IL-6 in macrophages and facilitate TJs restoration of the BSCB, which is beneficial for axon regeneration and motor functional recovery after SCI. Hence, Tocilizumab treatment is a potential therapeutic strategy for SCI.

Keyphrases

spinal cord injury
rheumatoid arthritis
juvenile idiopathic arthritis
rheumatoid arthritis patients
endothelial cells
spinal cord
neuropathic pain
poor prognosis
stem cells
disease activity
single molecule
binding protein
systemic lupus erythematosus
combination therapy